Brief: Vigil Neuroscience - Extends Projected Cash Runway Into Second Half Of 2025
03/01/2024 22:42
Jan 3 (Reuters) - Vigil Neuroscience Inc VIGL.O :
* VIGIL NEUROSCIENCE INC - EXTENDS PROJECTED CASH RUNWAY
INTO
SECOND HALF OF 2025
* VIGIL NEUROSCIENCE INC - ON TRACK TO REPORT INTERIM PHASE
1 DATA
FOR VG-3927 IN HEALTHY VOLUNTEERS IN MID-2024
* VIGIL NEUROSCIENCE INC - ON TRACK TO REPORT PHASE 2
RESULTS
FROM IGNITE CLINICAL TRIAL EVALUATING ILUZANEBART IN ALSP IN Q3
2024
Source text for Eikon: ID:nGNX2F9032
Further company coverage: VIGL.O
Recent news on Vigil Neuroscience
See all newsVigil Neuroscience Inc reports results for the quarter ended June 30 - Earnings Summary
Vigil Neuroscience Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
U.S. RESEARCH ROUNDUP-Ralph Lauren, Vigil Neuroscience, Workday
Deals of the day-Mergers and acquisitions